UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia

Clinical cancer research, 2019-10, Vol.25 (20), p.6021-6025

2019

Volltextzugriff (PDF)

Clinical study of suture anchors in the treatment of radial head fractures

BMC musculoskeletal disorders, 2023-02, Vol.24 (1), p.117-117, Article 117

2023

Volltextzugriff (PDF)

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical cancer research, 2023-02, Vol.29 (3), p.508-512

2023

Volltextzugriff (PDF)

Surgical technique and analysis of functional results of anchor for the treatment of olecranon fracture

Asian journal of surgery, 2023-03, Vol.46 (3), p.1336-1338

2023

Volltextzugriff (PDF)

Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation

European journal of clinical nutrition, 2018-08, Vol.72 (8), p.1167-1175

2018

Volltextzugriff (PDF)

The emissions from co-firing of biomass and torrefied biomass with coal in a chain-grate steam boiler

Journal of the Air & Waste Management Association (1995), 2019-12, Vol.69 (12), p.1467-1478

2019

Volltextzugriff (PDF)

Effect of suture-anchor internal fixation in the treatment of longitudinal patellar fractures through unicondylar replacement incision

Asian journal of surgery, 2022-07, Vol.45 (7), p.1498-1499

2022

Volltextzugriff (PDF)

Treatment of Hoffa fracture of femoral condyle with anchor combined with auxiliary fixation

Journal of back and musculoskeletal rehabilitation, 2023-01, Vol.36 (5), p.1185-1192

2023

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Clinical cancer research, 2021-04, Vol.27 (7), p.1836-1841

2021

Volltextzugriff (PDF)

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.65-65, Article 65

2022

Volltextzugriff (PDF)

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

The oncologist (Dayton, Ohio), 2009-11, Vol.14 (11), p.1131-1138

2009

Volltextzugriff (PDF)

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical cancer research, 2021-09, Vol.27 (17), p.4680-4684

2021

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3205-3209

2019

Volltextzugriff (PDF)

A Pilot Plant Study on the Autoclaving of Food Wastes for Resource Recovery and Reutilization

Sustainability, 2018-10, Vol.10 (10), p.3566

2018

Volltextzugriff (PDF)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

The oncologist (Dayton, Ohio), 2017-05, Vol.22 (5), p.585-591

2017

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Volltextzugriff (PDF)

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical cancer research, 2023-11, Vol.29 (21), p.4326-4330

2023

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Clinical cancer research, 2022-02, Vol.28 (3), p.446-451

2022

Volltextzugriff (PDF)

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

Clinical cancer research, 2021-08, Vol.27 (15), p.4142-4146

2021

Volltextzugriff (PDF)

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical cancer research, 2022-10, Vol.28 (19), p.4173-4177

2022

Volltextzugriff (PDF)

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Clinical cancer research, 2020-02, Vol.26 (3), p.532-536

2020

Volltextzugriff (PDF)

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2024-01, Vol.30 (2), p.269-273

2024

Volltextzugriff (PDF)

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical cancer research, 2024-01, Vol.30 (1), p.23-28

2024

Volltextzugriff (PDF)

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

The oncologist (Dayton, Ohio), 2017-11, Vol.22 (11), p.1347-1353

2017

Volltextzugriff (PDF)

1 – 25 von 13.365

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11.326)
Mit Volltextzugriff
(11.809)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(9.131)
Life Sciences & Biomedicine
(5.052)
Humans
(2.653)
Technology
(2.578)
Physical Sciences
(2.576)
Male
(1.459)
Female
(1.457)
Chemistry
(1.355)
Animals
(1.295)
Materials Science
(1.221)
Engineering
(1.076)
Physics
(1.020)
Science & Technology - Other Topics
(921)
Materials Science, Multidisciplinary
(920)
Middle Aged
(892)
Oncology
(780)
Adult
(755)
Mice
(688)
Aged
(657)
Biochemistry & Molecular Biology
(522)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia

Clinical study of suture anchors in the treatment of radial head fractures

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Surgical technique and analysis of functional results of anchor for the treatment of olecranon fracture

Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation

The emissions from co-firing of biomass and torrefied biomass with coal in a chain-grate steam boiler

Effect of suture-anchor internal fixation in the treatment of longitudinal patellar fractures through unicondylar replacement incision

Treatment of Hoffa fracture of femoral condyle with anchor combined with auxiliary fixation

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

A Pilot Plant Study on the Autoclaving of Food Wastes for Resource Recovery and Reutilization

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

Suchergebnisse filtern